Abstract
Substantial progress has been made in the past 10 years in the development and validation of outcome measures and refinement of trial methodology for systemic sclerosis (scleroderma, SSc). These advances in outcome measures have focused mostly on specific organ systems involved in SSc. Many of these new tools have been validated and subsequently adapted for use in multicenter clinical trials. Newer outcome measures in development are intended to more precisely quantify clinically meaningful change in specific organ systems, and some methods aim to assess overall disease burden in SSc. This review provides an update on currently used outcome measures in SSc with specific attention on newer tools and also describes methodology under development.
Similar content being viewed by others
References and Recommended Reading
Altman RD, Medsger TA Jr, Bloch DA, Michel BA: Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991, 34:403–413.
Merkel PA, Clements PJ, Reveille JD, et al.: Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. J Rheumatol 2003, 30:1630–1647.
White B, Bauer EA, Goldsmith LA, et al.: Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis. Arthritis Rheum 1995, 38:351–360.
Baroni SS, Santillo M, Bevilacqua F, et al.: Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006, 354:2667–2676.
Furst DE, Khanna D, Mattucci-Cerinic M, et al.: Scleroderma—developing measures of response. J Rheumatol 2005, 32:2477–2480.
Boers M, Brooks P, Strand CV, Tugwell P: The OMERACT filter for Outcome Measures in Rheumatology. J Rheumatol 1998, 25:198–199.
Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980, 23:581–590.
Clements PJ, Furst DE, Wong WK, et al.: High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999, 42:1194–1203.
Pope JE, Bellamy N, Seibold JR, et al.: A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001, 44:1351–1358.
Seibold JR, Korn JH, Simms R, et al.: Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000, 132:871–879.
Mayes MD, O’Donnell D, Rothfield NF, Csuka ME: Minocycline is not effective in systemic sclerosis: results of an open-label multicenter trial. Arthritis Rheum 2004, 50:553–557.
Clements P, Lachenbruch P, Siebold J, et al.: Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995, 22:1281–1285.
Clements PJ, Hurwitz EL, Wong WK, et al.: Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum 2000, 43:2445–2454.
Kissin EY, Schiller AM, Gelbard RB, et al.: Durometry for the assessment of skin disease in systemic sclerosis. Arthritis Rheum 2006, 55:603–609.
Merkel PA, Silliman N, Denton CP, et al.: Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial [abstract]. Arthritis Rheum 2004, 50:S419.
Moore TL, Lunt M, McManus B, et al.: Seventeen-point dermal ultrasound scoring system—a reliable measure of skin thickness in patients with systemic sclerosis. Rheumatology (Oxford) 2003, 42:1559–1563.
Akesson A, Hesselstrand R, Scheja A, Wildt M: Longitudinal development of skin involvement and reliability of high frequency ultrasound in systemic sclerosis. Ann Rheum Dis 2004, 63:791–796.
Steen VD, Conte C, Owens GR, Medsger TA Jr: Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994, 37:1283–1289.
Tashkin DP, Elashoff R, Clements PJ, et al.: Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006, 354:2655–2666.
Rubin LJ, Badesch DB, Barst RJ, et al.: Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002, 346:896–903.
Simonneau G, Barst RJ, Galie N, et al.: Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002, 165:800–804.
Badesch DB, Tapson VF, McGoon MD, et al.: Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000, 132:425–434.
Desai SR, Veeraraghavan S, Hansell DM, et al.: CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology 2004, 232:560–567.
Kazerooni EA, Martinez FJ, Flint A, et al.: Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 1997, 169:977–983.
Schettino IA, Ab’saber AM, Vollmer R, et al.: Accuracy of high resolution CT in assessing idiopathic pulmonary fibrosis histology by objective morphometric index. Pathol Res Pract 2002, 198:347–354.
Clements PJ, Goldin JG, Kleerup EC, et al.: Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis. Arthritis Rheum 2004, 50:1909–1917.
Miyamoto S, Nagaya N, Satoh T, et al.: Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000, 161(2 Pt 1):487–492.
Barst RJ, Rubin LJ, Long WA, et al.: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996, 334:296–302.
Buch MH, Denton CP, Furst DE, et al.: Sub-maximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: Reproducibility and correlations of the six minute walk test. Ann Rheum Dis 2006, Epub ahead of print.
Lederer DJ, Arcasoy SM, Wilt JS, et al.: Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006, 174:659–664.
Mahler DA, Weinberg DH, Wells CK, Feinstein AR: The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984, 85:751–758.
Khanna D, Clements PJ, Furst DE, et al.: Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum 2005, 52:592–600.
Martinez TY, Pereira CA, dos Santos ML, et al.: Evaluation of the short-form 36-item questionnaire to measure health-related quality of life in patients with idiopathic pulmonary fibrosis. Chest 2000, 117:1627–1632.
Steen VD, Medsger TA Jr: The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997, 40:1984–1991.
Sjogren RW: Gastrointestinal features of scleroderma. Curr Opin Rheumatol 1996, 8:569–575.
Khanna D, Hays RD, Park GS, et al.: Development of the scleroderma gastrointestinal tract 1.0 (SSc-GIT 1.0) quality of life instrument—preliminary report. Arthritis Rheum 2007, in press.
Horikoshi T, Matsuzaki T, Sekiguchi T: Effect of H2-receptor antagonists cimetidine and famotidine on interdigestive gastric motor activity and lower esophageal sphincter pressure in progressive systemic sclerosis. Intern Med 1994, 33:407–412.
Wang SJ, La JL, Chen DY, et al.: Effects of cisapride on oesophageal transit of solids in patients with progressive systemic sclerosis. Clin Rheumatol 2002, 21:43–45.
Merkel PA, Herlyn K, Martin RW, et al.: Measuring disease activity and functional status in patients with scleroderma and Raynaud’s phenomenon. Arthritis Rheum 2002, 46:2410–2420.
Fries R, Shariat K, von Wilmowsky H, Bohm M: Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation 2005, 112:2980–2985.
Wigley FM, Wise RA, Seibold JR, et al.: Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 1994, 120:199–206.
Dziadzio M, Denton CP, Smith R, et al.: Losartan therapy for Raynaud’s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 1999, 42:2646–2655.
Korn JH, Mayes M, Matucci CM, et al.: Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004, 50:3985–3993.
Khanna D, Furst DE, Clements PJ, et al.: Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol 2005, 32:832–840.
Cole JC, Khanna D, Clements PJ, et al.: Single-factor scoring validation for the Health Assessment Questionnaire-Disability Index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients. Qual Life Res 2006, 15:1383–1394.
Khanna D, Furst DE, Hays RD, et al.: Minimally important difference in diffuse systemic sclerosis—results from the D-penicillamine study. Ann Rheum Dis 2006, 65:1325–1329.
Weinstein MC, Siegel JE, Gold MR, et al.: Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996, 276:1253–1258.
Khanna D, Hays RD, Furst DE, et al.: Assessment of SF-6D, a preference measure, in systemic sclerosis [abstract]. Arthritis Rheum 2006, 52:S346.
Silman A, Akesson A, Newman J, et al.: Assessment of functional ability in patients with scleroderma: a proposed new disability assessment instrument. J Rheumatol 1998, 25:79–83.
Khanna D, Ahmed M, Furst DE, et al.: Health values of patients with systemic sclerosis. Arthritis Rheum 2007, 57:86–93.
Kissin EY, Merkel PA, Lafyatis R: Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis. Arthritis Rheum 2006, 54:3655–3660.
Williams MH, Handler CE, Akram R, et al.: Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 2006, 27:1485–1494.
Steen VD: Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005, 35:35–42.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Khanna, D., Merkel, P.A. Outcome measures in systemic sclerosis: An update on instruments and current research. Curr Rheumatol Rep 9, 151–157 (2007). https://doi.org/10.1007/s11926-007-0010-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11926-007-0010-5